ArticleJournal of cancer survivorship : research and practice2026
Late-onset epilepsy in survivors of childhood cancer outside the central nervous system: a study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.
Article in Journal of cancer survivorship : research and practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
purposeAlthough epilepsy has been reported in survivors of childhood cancer outside the central nervous system (CNS), little evidence exists on risk factors for this late complication. Our study aimed to identify risk factors of late-onset epilepsy.
methodsA case-cohort study was conducted within 5-year survivors of non-CNS childhood cancer from the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study, including 81 survivors diagnosed with late-onset epilepsy and a sub-cohort of 231 randomly selected survivors. Detailed treatment information was obtained from medical records. Incidence rate ratios (IRRs) and 95% confidence intervals (CIs) were calculated to assess the association between treatment-related factors and epilepsy.
resultsSurvivors of acute lymphoblastic leukemia (ALL) and other types of leukemia exhibited significantly higher IRRs for epilepsy compared to survivors of solid tumors (ALL: 4.4, 95% CI 2.2-8.5; other leukemia: 14.1, 95% CI 3.4-57.9). Relapse was associated with an increased IRR of epilepsy (3.5, 95% CI 1.5-8.6). Specifically, survivors of relapsed leukemia demonstrated a high IRR for epilepsy (11.4, 95% CI 3.5 - 37.3) compared to non-relapsed survivors. No association was found between epilepsy and bone marrow transplantation, radiotherapy, total body irradiation, or treatment with specific chemotherapeutic agents. Finally, survivors diagnosed after 1990 had a decreased IRR of epilepsy (0.4, 95% CI 0.2 - 0.8) compared to survivors diagnosed in 1970 - 1979.
conclusionRelapsed leukemia survivors were at increased risk for late-onset epilepsy. IMPLICATIONS FOR CANCER SURVIVORS: Awareness of the risk of epilepsy in leukemia survivors is important, especially among those with relapse, to detect and manage epilepsy early and mitigate its impact on quality of life.
Indexed as
Identifiers
40238072What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.